Brief: Alimera Sciences Inc-Completed Enrollment For New Day Clinical Trial, For Iluvien As Therapy In Patients Diagnosed With Diabetic Macular Edema
24/05/2023 13:12
May 24 (Reuters) - Alimera Sciences Inc ALIM.O :
* ALIMERA SCIENCES INC-COMPLETED ENROLLMENT FOR NEW DAY
CLINICAL
TRIAL, FOR ILUVIEN AS THERAPY IN PATIENTS DIAGNOSED WITH
DIABETIC MACULAR EDEMA
Source text for Eikon: ID:nGNXbvJxcD
Further company coverage: ALIM.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Alimera Sciences
See all newsBrief: ANI Pharmaceuticals And Alimera Sciences Announce Closing Date Of Merger
Brief: Ani Pharmaceuticals Provides Update On Closing Of Acquisition Of Alimera Sciences
U.S. STOCKS ON THE MOVE-JPMorgan, automakers, energy firms
U.S. STOCKS ON THE MOVE-Arrowhead Pharma, Boeing, Centessa Pharma
Brief: Alimera Sciences Files Lawsuit To Compel ANI To Close Merger